top of page
54 million Americans suffer from obstructive sleep apnea (OSA) every night.
2x
Risk of heart attack, stroke and diabetes.
50%
Patients fail CPAP therapy.
$150 Billion
Spent yearly on untreated OSA in the US
Current treatment methods are invasive and ineffective
Introducing Somnair
The first non-invasive treatment for
OSA sufferers
Somnair is a novel non-invasive neurostimuation device that opens the airway using a proprietary therapy delivery system.
Patent Pending
Neurostimulation Therapy
Non-Invasive
Deployed at Home
bottom of page